The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Prediabetic State

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Prediabetic State

 

High impact information on Prediabetic State

  • This association suggests the abnormal expression of receptor isoforms as a characteristic of the prediabetic state and supports the notion of a connection of this aberration with the pathogenesis of NIDDM [6].
  • The 65KD isoform of GAD is considered to be a major target autoantigen in many humans with autoimmune prediabetes or diabetes [7].
  • In marked contrast, the degree of CD4/CD8 depression found in individuals with prediabetes or long-term diabetes failed to correlate with either CIAA (r = 0.32) or ICA (r = 0.29) levels [8].
  • Despite the persistent enhancement of glucose transport rate, concentration of glucose transporters in the intracellular pool was restored only to its prediabetic state [9].
  • One hallmark of the insulin-resistant state of prediabetes and overt type 2 diabetes is an impaired ability of insulin to activate glucose transport in skeletal muscle, due to defects in IRS-1-dependent signaling [10].
 

Chemical compound and disease context of Prediabetic State

  • It is postulated that the genetic prediabetic state with or without glucose intolerance might be associated with significant alterations of mean retinal circulation time independent of age and per cent ideal weight [11].
  • Thus, arginine induced hyperglucagonemia could not be identified as a characteristic of the prediabetic state in Pima Indians [12].
  • OBJECTIVE--To investigate the effect of an antiedematous therapy with the histamine antagonist ketotifen on beta-cell function in late prediabetes [13].
  • To test the hypothesis that exposure to cadmium is associated with impaired fasting glucose and type 2 diabetes, we examined the associations between urinary cadmium and the prevalence of impaired fasting glucose (prediabetes) and diabetes in the Third National Health and Nutrition Examination Survey (NHANES III) [14].
  • Current prevention strategies use a combination of autoantibody marker testing and beta-cell function testing to identify individuals with 'prediabetes'. The most useful autoantibodies for prediabetes screening include islet cell autoantibodies, insulin autoantibodies, glutamic acid decarboxylase autoantibodies and IA-2 autoantibodies [15].
 

Biological context of Prediabetic State

 

Anatomical context of Prediabetic State

 

Gene context of Prediabetic State

 

Analytical, diagnostic and therapeutic context of Prediabetic State

References

  1. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Benjamin, S.M., Valdez, R., Geiss, L.S., Rolka, D.B., Narayan, K.M. Diabetes Care (2003) [Pubmed]
  2. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Pedrazzini, T. Neuropeptides (2004) [Pubmed]
  3. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study. Gokulakrishnan, K., Deepa, R., Mohan, V., Gross, M.D. Metab. Clin. Exp. (2006) [Pubmed]
  4. DiaPep277 (DeveloGen). Giannoukakis, N. Current opinion in investigational drugs (London, England : 2000) (2005) [Pubmed]
  5. Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus. Hayden, M.R. JOP (2002) [Pubmed]
  6. Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes. Mosthaf, L., Eriksson, J., Häring, H.U., Groop, L., Widen, E., Ullrich, A. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  7. Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Liu, J., Purdy, L.E., Rabinovitch, S., Jevnikar, A.M., Elliott, J.F. Diabetes (1999) [Pubmed]
  8. T-lymphocyte changes linked to autoantibodies. Association of insulin autoantibodies with CD4+CD45R+ lymphocyte subpopulation in prediabetic subjects. Faustman, D., Schoenfeld, D., Ziegler, R. Diabetes (1991) [Pubmed]
  9. Reversal of insulin resistance in diabetic rat adipocytes by insulin therapy. Restoration of pool of glucose transporters and enhancement of glucose-transport activity. Karnieli, E., Armoni, M., Cohen, P., Kanter, Y., Rafaeloff, R. Diabetes (1987) [Pubmed]
  10. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Henriksen, E.J. Free Radic. Biol. Med. (2006) [Pubmed]
  11. Mean retinal circulation time as determined by fluorescein angiography in normal, prediabetic, and chemical-diabetic subjects. Soeldner, J.S., Christacopoulos, P.S., Gleason, R.E. Diabetes (1976) [Pubmed]
  12. Normal glucagon response to arginine infusion in "prediabetic" Pima Indians. Aronoff, S.L., Bennett, P.H., Rushforth, N.B., Miller, M., Unger, R.H. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  13. Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen. Böhmer, K.P., Kolb, H., Kuglin, B., Zielasek, J., Hübinger, A., Lampeter, E.F., Weber, B., Kolb-Bachofen, V., Jastram, H.U., Bertrams, J. Diabetes Care (1994) [Pubmed]
  14. Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III. Schwartz, G.G., Il'yasova, D., Ivanova, A. Diabetes Care (2003) [Pubmed]
  15. Pharmacological approaches to the prevention of autoimmune diabetes. Winter, W.E., House, D.V., Schatz, D. Drugs (1997) [Pubmed]
  16. Beta Cell Function, Insulin Resistance and Plasma Adiponectin Concentrations are Predictors for the Change of Postprandial Glucose in Non-diabetic Subjects at Risk for Type 2 Diabetes. Thamer, C., Haap, M., Heller, E., Joel, L., Braun, S., Tschritter, O., Haring, H., Fritsche, A. Horm. Metab. Res. (2006) [Pubmed]
  17. Obesity and high blood pressure: a clinical phenotype for the insulin resistance syndrome in African Americans. Campbell, K.L., Kushner, H., Falkner, B. Journal of clinical hypertension (Greenwich, Conn.) (2004) [Pubmed]
  18. The acetylcholine-hypersensitive model of diabetic KK-CA(y) mice analyzed with pulse rate, and modified by repeated cold stress and by adrenalectomy. Kimura, I., Matsui, T., Kimura, M. J. Pharmacobio-dyn. (1990) [Pubmed]
  19. Postpartum oral glucose tolerance tests in mothers of macarosomic infants: inadequacy of current antenatal test criteria in detecting prediabetic state. Bukulmez, O., Durukan, T. Eur. J. Obstet. Gynecol. Reprod. Biol. (1999) [Pubmed]
  20. Beta-cell behaviour during the prediabetic stage. Part II. Non-insulin-dependent and insulin-dependent diabetes mellitus. Homo-Delarche, F. Diabetes Metab. (1997) [Pubmed]
  21. In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects. Kretowski, A., Myśliwiec, J., Szelachowska, M., Brzozowski, C., Pietruczuk, M., Kinalska, I. Arch. Immunol. Ther. Exp. (Warsz.) (1999) [Pubmed]
  22. B-cell hyperresponsiveness to glucose in NIDDM during prediabetes. Sato, Y., Ishihara, F., Hashizume, K., Aizawa, T. Adv. Exp. Med. Biol. (1997) [Pubmed]
  23. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Kim, S.G., Ryu, O.H., Kim, H.Y., Lee, K.W., Seo, J.A., Kim, N.H., Choi, K.M., Lee, J., Baik, S.H., Choi, D.S. Eur. J. Endocrinol. (2006) [Pubmed]
  24. Defective activation of p21ras in peripheral blood mononuclear cells from patients with insulin dependent diabetes mellitus. Rapoport, M.J., Mor, A., Vardi, P., Ramot, Y., Levi, O., Bistritzer, T. Autoimmunity (1999) [Pubmed]
  25. Is inflammation a causal chain between low socioeconomic status and type 2 diabetes? Results from the KORA Survey 2000. Rathmann, W., Haastert, B., Giani, G., Koenig, W., Imhof, A., Herder, C., Holle, R., Mielck, A. Eur. J. Epidemiol. (2006) [Pubmed]
  26. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Dumasia, R., Eagle, K.A., Kline-Rogers, E., May, N., Cho, L., Mukherjee, D. Current drug targets. Cardiovascular & haematological disorders (2005) [Pubmed]
  27. Glucagon secretion in subjects with prediabetes, diabetes mellitus and obesity. Slavnov, V.N., Epshtein, E.V., Efimov, A.S., Malinkovich, V.D., Stepanenko, L.I. Endocrinologie. (1979) [Pubmed]
  28. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. Byrne, M.M., Göke, B. Diabet. Med. (1996) [Pubmed]
  29. Idiopathic neuropathy, prediabetes and the metabolic syndrome. Gordon Smith, A., Robinson Singleton, J. J. Neurol. Sci. (2006) [Pubmed]
  30. Prediabetes: genetic, immunological and metabolical aspects. Verrotti, A., Chiarelli, F., Capani, F., Morgese, G. Panminerva medica. (1993) [Pubmed]
  31. Decreased levels of plasma adiponectin in prediabetes, Type 2 diabetes and coronary artery disease. Yaturu, S., Bridges, J.F., Subba Reddy, D.R. Med. Sci. Monit. (2006) [Pubmed]
 
WikiGenes - Universities